BioSpace News Archive

Most recently, Mr. Cooper was the CFO of Receptos from 2013 until its sale in 2015 to Celgene for $7.8B.

This study is an important step in the drug development pathway for a treatment for shingles, a debilitating infection of human skin by VZV.

Vestagen today announced that the protective properties of VESTEX will be discussed in two scientific presentations at the upcoming IHI 2017 National Forum on Quality Improvement in Health Care conference being held December 10-13 in Orlando, FL.

Generational Equity is pleased to announce a majority acquisition of its client, LGM Pharma, by New Harbor Capital LLC.

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

The data presented is expected to demonstrate the potential for CGP to improve disease classification, to offer personalized prognostic information and to support therapeutic treatment decision making by informing treating physicians about the use of novel treatment options, including cancer immunotherapies.

Results showed these trastuzumab-ICOSL “V-mAbs” promoted T cell proliferation and cytokine secretion and enhanced killing of tumor cells.

Narayan brings extensive leadership experience in business development, operations and legal operations within the biotechnology and pharmaceuticals industries, most recently through his role as Vice President and Head of Transactions at Johnson & Johnson (J&J) Innovation in Boston.

CALQUENCE (acalabrutinib) is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

These data, presented at the 22nd biennial HEP DART meeting held in Kona, Hawaii, from Dec. 3-7, indicate that multiple doses of an RNAi-based therapy may lead to a host response that is sustained after therapy is concluded.